View Clinical Trial (Medical Research Study)

Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI) - NCT00826228-60611(Clinical Trial 264903)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Chicago
State:  
IL
Zip Code: 60611
Conditions: Osteoporosis - Bone Loss - Spinal Cord Injury
Purpose: Individuals with spinal cord injury sustain significant loss of bone mass in their lower extremities (20-40% or more). This study evaluates the ability of PTH and weight-bearing, two interventions that build bone, to increase bone mass in this population.
Study summary: This pilot project aims to evaluate PTH with weight-bearing in a group of individuals with chronic SCI and loss of bone mass in their lower extremities. A convenience sample of 12 people with SCI will be enrolled into a 6 month study assessing the effects of a weight-bearing regime plus daily PTH (Forteo 20ug sc) on BMD and bone markers. Subjects will be evaluated at 3 and 6 months after initiating treatment with measurement of bone density as well as bone markers of formation and resorption. An optional extension to 12 months will be offered to all subjects.
Criteria: Inclusion Criteria: 1. Age 18-75 years 2. Complete SCI - total loss of motor function below level of lesion 3. Capable of positioning to have DEXA performed 4. Capable of undertaking the weight-bearing exercise regime 5. Capable of reading and understanding informed consent document 6. Able to self-administer PTH or have someone in the family who can do so 7. T score <-2.5 or Z score <-1.5 on evaluation of total hip BMD 8. No known endocrinopathies 9. Normal TSH levels 10. Normal 25-OH vitamin D levels 11. Normal calcium levels 12. Normal renal function (creatinine <2.0mg/dl) 13. Able to return for all follow-up visits Exclusion Criteria: 1. Surgical or other intervention resulting in metal or anatomy precluding obtaining DEXA and/or MRI measurements 2. Other medical conditions that in the opinion of the investigator would preclude the subject from completing the study 3. History of malignancy 4. History of radiation therapy 5. Unable to self-administer PTH or have it administered 6. Elevated liver function tests >2x normal 7. For males, significantly abnormal free testosterone levels 8. Currently being prescribed anti-convulsants 9. Currently being prescribed glucocorticoids, other than inhaled glucocorticoids 10. Currently being prescribed any bone-active agents, including any bisphosphonate, raloxifene, hormone therapy (estrogen and estrogen/progestin), calcitonin or strontium-containing compounds. 11. No previous history of bisphosphonate use 12. No previous use of other bone-specific agents during past 2 years
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: July 21, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.